Nice Quarter from A...
Health Care: Drugs
YM Biosciences Inc. (YMI: AMEX)
$2.33 0.01 | 0.43%
02/08/12 - 04:00 PM ET
936.06K / 1.30M
Vol / Avg. Vol:2.35 / 2.32
Open / Prev. Close:2.32 - 2.38
Today's Range:1.03 - 3.78
52 Wk Range:41.46%
Performance YTD:TheStreet Rating:
Portfolios with YMI
- Portfolio NameUser Type
- Contributor10 Biotech Stocks Loved and...
- Contributor11 Biotech Stocks Loved or ...
- Contributor10 Biotech Trades for Secon...
- Contributor10 Pharma Stocks Under $3
- Contributor4 Biotech Penny Stocks to Buy
- ContributorCancer Drug Stocks to Trade...
- Contributor6 Penny Stocks for the Biot...
- UserSUPRATRADE HOT STOCKS (BUY ...
- User©SUPRATRADE HOT STOCKS (...
- UserDiscretionary #1
Latest YMI Headlines from TheStreet
- Biotech Buyside Predictions for 2012 01.05.12 | 09:01 am
- Biotech Stock Live Chat: 2012 Preview 12.15.11 | 11:12 am
- YM Bio's Myelofibrosis Drug Is For Real 12.12.11 | 06:12 pm
- Onyx Trips, Ariad and Pharmacyclics Shine at Blood Cancer Meeting 12.12.11 | 07:12 am
- The Next Big Thing in Biotech: YM Biosciences
12.09.11 | 06:12 am - Biotech Stock Mailbag: YM Bio, Exact, Peregrine 12.09.11 | 06:12 am
- YMI... WTF?!? 11.29.11 | 11:11 am
- FDA Approves Incyte Myelofibrosis Drug 11.16.11 | 11:11 am
- 10 Biotech Stocks Loved and Hated by Wall Street's Top Investment Pros 11.15.11 | 06:11 am
- 11 Biotech Stocks Loved or Hated by Hedge Funds 08.17.11 | 06:08 am
Press Releases for YMI
- YM BioSciences Reports Updated Phase I/II Data For Its JAK1/JAK2 Inhibitor CYT387 At ASH 2011 - PR Newswire 12.12.11 | 05:12 pm
- YM BioSciences To Report Updated Phase I/II Data For CYT387 At ASH 2011 - PR Newswire 11.07.11 | 12:11 pm
- YM BioSciences Nimotuzumab Results Reported At SIOP Conference - PR Newswire 10.31.11 | 07:10 am
- YM BioSciences Proposes Dr. Catherine Mackey And Dr. Nicole Onetto For Nomination To Board Of Directors - PR Newswire 10.19.11 | 07:10 am
- YM BioSciences Initiates Phase II BID Trial With CYT387 In Myelofibrosis - PR Newswire 09.28.11 | 07:09 am
- YM BioSciences Announces Nimotuzumab Data To Be Reported At 2011 ECCO-ESMO Conference - PR Newswire 09.26.11 | 09:09 am
- CORRECTION FROM SOURCE: YM BioSciences Reports Fiscal 2011 Year End Operational And Financial Results - PR Newswire 09.23.11 | 05:09 pm
- YM BioSciences JAK Inhibitor CYT387 Shown Active In Multiple Myeloma - PR Newswire 08.04.11 | 09:08 am
- YM BioSciences Files Preliminary Base Shelf Prospectus - PR Newswire 07.07.11 | 05:07 pm
- YM BioSciences Reports Interim Phase I/II Data For Its JAK1/JAK2 Inhibitor CYT387 At ASCO - PR Newswire 06.03.11 | 03:06 pm
Partner Headlines for YMI
- Zacks' Voice of the People highlights opportunities with Ann Taylor, Team and YMI BioSciences - Press Releases - Zacks 01.19.12 | 09:01 am
- YM's Positive Results Have Incyte Investors Worried - Seeking Alpha 12.15.11 | 09:12 am
- Q3 Micro-Cap Biotech Picks By The World's Largest Fund Managers - Seeking Alpha 12.08.11 | 09:12 am
- Incyte JAK Inhibitor Awaits Certain Approval - Seeking Alpha 11.14.11 | 09:11 am
- 19 Small Cap Stocks Boosted By Institutional Buying - Seeking Alpha 10.11.11 | 08:10 am
- Hearing Positive Drug Chatter in YM Bio Sciences - Benzinga 08.19.11 | 01:08 pm
- Morning Market Losers - Benzinga 06.06.11 | 09:06 am
- Drugs to Watch at ASCO 2011 - Seeking Alpha 06.02.11 | 08:06 am
- 24 Stocks Under $5 Undervalued Relative to Target Price - Seeking Alpha 05.24.11 | 08:05 am
- ASCO 2011: Opportunities for Biotech Investor Success and Failure - Seeking Alpha 05.02.11 | 09:05 am
